Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
- Autores
- Mojica, María F.; De La Cadena, Elsa; Ríos, Rafael; García Betancur, Juan Carlos; Díaz, Lorena; Reyes, Jinnethe; Hernández Gómez, Cristhian; Radice, Marcela Alejandra; Gales, Ana C.; Castañeda Méndez, Paulo; Munita, José M.; Pallares, Christian José; Martínez, José R. W.; Villegas, María Virginia
- Año de publicación
- 2022
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Objectives: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction of TOL into the clinical practice. Methods: Clinical isolates of P. aeruginosa (n = 504) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to TOL were determined by standard broth microdilution and interpreted according to CLSI breakpoints. Initially, production of carbapenemases in TOL non-susceptible isolates was assessed by Rapidec® followed by qPCR to detect blaKPC, blaNDM-1, blaVIM, and blaIMP. Illumina® WGS was performed for isolates in which non-susceptibility to TOL was not mediated by carbapenemases. Results: A total of 158 (31.3%) isolates were non-susceptible to TOL. In 74 (46.8%) of these isolates, non-susceptibility to TOL was explained by the production of at least one carbapenemase. WGS revealed that some isolates carried ESBLs, mutated blaPDC and ampD, associated with decreased susceptibility to TOL. Conclusion: Substitutions found in PDC and carbapenemase production were the most common presumed mechanisms of resistance to TOL detected in this study. This study shows that epidemiological surveillance is warranted to monitor the emergence of novel mechanisms of resistance to TOL that might compromise its clinical utility.
Fil: Mojica, María F.. Case Western Reserve University; Estados Unidos
Fil: De La Cadena, Elsa. Universidad El Bosque;
Fil: Ríos, Rafael. Universidad El Bosque;
Fil: García Betancur, Juan Carlos. Universidad El Bosque;
Fil: Díaz, Lorena. Universidad El Bosque;
Fil: Reyes, Jinnethe. Universidad El Bosque;
Fil: Hernández Gómez, Cristhian. Universidad El Bosque;
Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Gales, Ana C.. Universidade Federal de Sao Paulo; Brasil
Fil: Castañeda Méndez, Paulo. Fundacion Clinica Medica Sur; México
Fil: Munita, José M.. Universidad del Desarrollo; Chile
Fil: Pallares, Christian José. Universidad El Bosque;
Fil: Martínez, José R. W.. Universidad del Desarrollo; Chile
Fil: Villegas, María Virginia. Universidad El Bosque; - Materia
-
ANTIBIOTIC RESISTANCE
CEFTOLOZANE/TAZOBACTAM
LATIN AMERICA
MOLECULAR MECHANISMS
PSEUDOMONAS AERUGINOSA - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/217847
Ver los metadatos del registro completo
id |
CONICETDig_9e7b54e9b955a1fea6bff90478ef5725 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/217847 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countriesMojica, María F.De La Cadena, ElsaRíos, RafaelGarcía Betancur, Juan CarlosDíaz, LorenaReyes, JinnetheHernández Gómez, CristhianRadice, Marcela AlejandraGales, Ana C.Castañeda Méndez, PauloMunita, José M.Pallares, Christian JoséMartínez, José R. W.Villegas, María VirginiaANTIBIOTIC RESISTANCECEFTOLOZANE/TAZOBACTAMLATIN AMERICAMOLECULAR MECHANISMSPSEUDOMONAS AERUGINOSAhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Objectives: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction of TOL into the clinical practice. Methods: Clinical isolates of P. aeruginosa (n = 504) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to TOL were determined by standard broth microdilution and interpreted according to CLSI breakpoints. Initially, production of carbapenemases in TOL non-susceptible isolates was assessed by Rapidec® followed by qPCR to detect blaKPC, blaNDM-1, blaVIM, and blaIMP. Illumina® WGS was performed for isolates in which non-susceptibility to TOL was not mediated by carbapenemases. Results: A total of 158 (31.3%) isolates were non-susceptible to TOL. In 74 (46.8%) of these isolates, non-susceptibility to TOL was explained by the production of at least one carbapenemase. WGS revealed that some isolates carried ESBLs, mutated blaPDC and ampD, associated with decreased susceptibility to TOL. Conclusion: Substitutions found in PDC and carbapenemase production were the most common presumed mechanisms of resistance to TOL detected in this study. This study shows that epidemiological surveillance is warranted to monitor the emergence of novel mechanisms of resistance to TOL that might compromise its clinical utility.Fil: Mojica, María F.. Case Western Reserve University; Estados UnidosFil: De La Cadena, Elsa. Universidad El Bosque;Fil: Ríos, Rafael. Universidad El Bosque;Fil: García Betancur, Juan Carlos. Universidad El Bosque;Fil: Díaz, Lorena. Universidad El Bosque;Fil: Reyes, Jinnethe. Universidad El Bosque;Fil: Hernández Gómez, Cristhian. Universidad El Bosque;Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Gales, Ana C.. Universidade Federal de Sao Paulo; BrasilFil: Castañeda Méndez, Paulo. Fundacion Clinica Medica Sur; MéxicoFil: Munita, José M.. Universidad del Desarrollo; ChileFil: Pallares, Christian José. Universidad El Bosque;Fil: Martínez, José R. W.. Universidad del Desarrollo; ChileFil: Villegas, María Virginia. Universidad El Bosque;Frontiers Media2022-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/217847Mojica, María F.; De La Cadena, Elsa; Ríos, Rafael; García Betancur, Juan Carlos; Díaz, Lorena; et al.; Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries; Frontiers Media; Frontiers in Microbiology; 13; 10-2022; 1-81664-302XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3389/fmicb.2022.1035609info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:49:38Zoai:ri.conicet.gov.ar:11336/217847instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:49:39.129CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries |
title |
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries |
spellingShingle |
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries Mojica, María F. ANTIBIOTIC RESISTANCE CEFTOLOZANE/TAZOBACTAM LATIN AMERICA MOLECULAR MECHANISMS PSEUDOMONAS AERUGINOSA |
title_short |
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries |
title_full |
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries |
title_fullStr |
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries |
title_full_unstemmed |
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries |
title_sort |
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries |
dc.creator.none.fl_str_mv |
Mojica, María F. De La Cadena, Elsa Ríos, Rafael García Betancur, Juan Carlos Díaz, Lorena Reyes, Jinnethe Hernández Gómez, Cristhian Radice, Marcela Alejandra Gales, Ana C. Castañeda Méndez, Paulo Munita, José M. Pallares, Christian José Martínez, José R. W. Villegas, María Virginia |
author |
Mojica, María F. |
author_facet |
Mojica, María F. De La Cadena, Elsa Ríos, Rafael García Betancur, Juan Carlos Díaz, Lorena Reyes, Jinnethe Hernández Gómez, Cristhian Radice, Marcela Alejandra Gales, Ana C. Castañeda Méndez, Paulo Munita, José M. Pallares, Christian José Martínez, José R. W. Villegas, María Virginia |
author_role |
author |
author2 |
De La Cadena, Elsa Ríos, Rafael García Betancur, Juan Carlos Díaz, Lorena Reyes, Jinnethe Hernández Gómez, Cristhian Radice, Marcela Alejandra Gales, Ana C. Castañeda Méndez, Paulo Munita, José M. Pallares, Christian José Martínez, José R. W. Villegas, María Virginia |
author2_role |
author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
ANTIBIOTIC RESISTANCE CEFTOLOZANE/TAZOBACTAM LATIN AMERICA MOLECULAR MECHANISMS PSEUDOMONAS AERUGINOSA |
topic |
ANTIBIOTIC RESISTANCE CEFTOLOZANE/TAZOBACTAM LATIN AMERICA MOLECULAR MECHANISMS PSEUDOMONAS AERUGINOSA |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Objectives: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction of TOL into the clinical practice. Methods: Clinical isolates of P. aeruginosa (n = 504) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to TOL were determined by standard broth microdilution and interpreted according to CLSI breakpoints. Initially, production of carbapenemases in TOL non-susceptible isolates was assessed by Rapidec® followed by qPCR to detect blaKPC, blaNDM-1, blaVIM, and blaIMP. Illumina® WGS was performed for isolates in which non-susceptibility to TOL was not mediated by carbapenemases. Results: A total of 158 (31.3%) isolates were non-susceptible to TOL. In 74 (46.8%) of these isolates, non-susceptibility to TOL was explained by the production of at least one carbapenemase. WGS revealed that some isolates carried ESBLs, mutated blaPDC and ampD, associated with decreased susceptibility to TOL. Conclusion: Substitutions found in PDC and carbapenemase production were the most common presumed mechanisms of resistance to TOL detected in this study. This study shows that epidemiological surveillance is warranted to monitor the emergence of novel mechanisms of resistance to TOL that might compromise its clinical utility. Fil: Mojica, María F.. Case Western Reserve University; Estados Unidos Fil: De La Cadena, Elsa. Universidad El Bosque; Fil: Ríos, Rafael. Universidad El Bosque; Fil: García Betancur, Juan Carlos. Universidad El Bosque; Fil: Díaz, Lorena. Universidad El Bosque; Fil: Reyes, Jinnethe. Universidad El Bosque; Fil: Hernández Gómez, Cristhian. Universidad El Bosque; Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Gales, Ana C.. Universidade Federal de Sao Paulo; Brasil Fil: Castañeda Méndez, Paulo. Fundacion Clinica Medica Sur; México Fil: Munita, José M.. Universidad del Desarrollo; Chile Fil: Pallares, Christian José. Universidad El Bosque; Fil: Martínez, José R. W.. Universidad del Desarrollo; Chile Fil: Villegas, María Virginia. Universidad El Bosque; |
description |
Objectives: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction of TOL into the clinical practice. Methods: Clinical isolates of P. aeruginosa (n = 504) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to TOL were determined by standard broth microdilution and interpreted according to CLSI breakpoints. Initially, production of carbapenemases in TOL non-susceptible isolates was assessed by Rapidec® followed by qPCR to detect blaKPC, blaNDM-1, blaVIM, and blaIMP. Illumina® WGS was performed for isolates in which non-susceptibility to TOL was not mediated by carbapenemases. Results: A total of 158 (31.3%) isolates were non-susceptible to TOL. In 74 (46.8%) of these isolates, non-susceptibility to TOL was explained by the production of at least one carbapenemase. WGS revealed that some isolates carried ESBLs, mutated blaPDC and ampD, associated with decreased susceptibility to TOL. Conclusion: Substitutions found in PDC and carbapenemase production were the most common presumed mechanisms of resistance to TOL detected in this study. This study shows that epidemiological surveillance is warranted to monitor the emergence of novel mechanisms of resistance to TOL that might compromise its clinical utility. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-10 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/217847 Mojica, María F.; De La Cadena, Elsa; Ríos, Rafael; García Betancur, Juan Carlos; Díaz, Lorena; et al.; Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries; Frontiers Media; Frontiers in Microbiology; 13; 10-2022; 1-8 1664-302X CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/217847 |
identifier_str_mv |
Mojica, María F.; De La Cadena, Elsa; Ríos, Rafael; García Betancur, Juan Carlos; Díaz, Lorena; et al.; Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries; Frontiers Media; Frontiers in Microbiology; 13; 10-2022; 1-8 1664-302X CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.3389/fmicb.2022.1035609 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers Media |
publisher.none.fl_str_mv |
Frontiers Media |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613535609389056 |
score |
13.070432 |